Senolytic CAR T cells: what a mouse study reported
A 2024 Nature Aging paper describes anti-uPAR CAR T cells in mice. It is not a human longevity trial and not a protocol.
CAR-T senolytic research
CAR-T senolytic research
CAR T cells aimed at senescent cells have been reported in mice. This site does not turn that report into a human therapy. Human lifespan extension is not established here. A disease approval is not an anti-aging approval.
Latest discoveries
Featured research
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL, Jones LW, Sadelain M, Lowe SW
The abstract reports that uPAR-positive senescent cells accumulated with aging, that anti-uPAR CAR T cells could target them, and that treatment improved exercise capacity in physiological aging and glucose tolerance in aged mice and in mice on a high-fat diet. A single administration is described as sufficient for a lasting effect in those experiments.
The abstract describes mice, not a human trial. No human sample size is stated. This is not evidence of a longer human life.
The future
The open questions are measurement, safety and whether a change in a marker changes how people function. Those are research questions, not results.
Evidence grades stay in the Longevity Explorer. A disease study is not an anti-aging approval. Explorer
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.